Natural Products Analysis
https://www.sciltp.com/journals/npa

Review

Check for updates

Methodological and Mechanistic Advances in Evaluating the Antidiabetic Activity of Plant Extracts

Lutfun Nahar

Centre for Natural Products Discovery, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK; L.Nahar@ljmu.ac.uk or profnahar@outlook.com

How To Cite: Nahar, L. Methodological and Mechanistic Advances in Evaluating the Antidiabetic Activity of Plant Extracts. *Natural Products Analysis* **2026**, *2*(1), 100007. https://doi.org/10.53941/npa.2026.100007

Received: 24 February 2026
Revised: 6 April 2026
Accepted: 15 April 2026
Published: 30 April 2026

Abstract: Plant extracts remain central to antidiabetic discovery because their phytochemicals influence biochemical, cellular and physiological pathways linked with glucose regulation. These preparations inhibit digestive enzymes, modulate insulin-linked signalling, reduce oxidative stress, suppress inflammatory mediators and support β-cell resilience. Reported activity depends on methodological design and assay calibration. Recent advances strengthened early evaluation through refined *in vitro* enzyme assays, glucose handling models and calibrated cellular platforms. *In vivo* studies provide clearer evidence of glycaemic modulation, lipid correction and tissue protection when dosing and induction conditions are reported with full transparency. *In silico* systems reinforce laboratory findings through predicted multi-target binding profiles and ligand-stability modelling. Multi-omics technologies deepen mechanistic interpretation by mapping metabolite shifts, transcriptional responses and proteomic patterns that connect extract chemistry with metabolic outcomes. Integrated workflows now combine chemical profiling with *in vitro*, *in vivo* and computational systems to enhance reproducibility and improve mechanistic resolution across methodological tiers. Persistent challenges include extraction heterogeneity, assay variability, incomplete standardisation and uncertainty regarding model translatability across experimental tiers. This review examines methodological and mechanistic advances that strengthen the reliability and interpretability of plant-derived antidiabetic research.

Keywords: antidiabetic-assessment methodologies; plant-extract evaluation; phytochemical profiling; multi-omics analysis; methodological standardisation

1. Introduction

Diabetes mellitus represents a chronic metabolic disorder defined by persistent hyperglycaemia and progressive disruption of carbohydrate, lipid and protein homeostasis. Global prevalence continues to rise because demographic change, dietary transition and metabolic vulnerability increase disease risk across many regions [1]. Conventional antidiabetic agents maintain glycaemia through insulin sensitisation, secretagogue activity or digestive enzyme inhibition, yet limited tolerability, declining long-term efficacy and restricted pancreatic protection remain evident across experimental systems [2,3]. These constraints strengthen interest in plant-derived preparations with multi-target biochemical relevance.

Medicinal plants contain diverse metabolites, including polyphenols, flavonoids, alkaloids, terpenoids, polysaccharides and saponins, each influencing digestive enzymes, oxidative pathways, inflammatory mediators and insulin-linked signalling mechanisms associated with metabolic stability [4]. Extracts from *Gymnema sylvestre* [5], *Rhazya stricta* [6], *Paeonia japonica* [7], *Punica granatum* [8], *Citrus aurantium* [9], *Ajuga iva* [10,11], *Galega officinalis* [12] and *Solidago virgaurea* [13] demonstrate digestive enzyme inhibition, enhanced glucose uptake, insulin-linked behaviour and preserved β-cell structure across multiple tiers.

Recent methodological advances strengthened early assessment of extract behaviour through refined *in vitro* enzyme assays using standardised substrates, calibrated buffers and defined detection parameters [14,15]. Additional *in vitro* assays address dipeptidyl peptidase 4 inhibition, glycation suppression and antioxidant responses and support early mechanistic interpretation [16,17]. Cell-based systems evaluate glucose uptake, mitochondrial behaviour, oxidative status and GLUT4 mobilisation under physiologically relevant exposure conditions and reveal extract-specific modulation of AMPK-, PI3K- and AKT-linked pathways [18].

In vivo models integrate biochemical and cellular signals because they incorporate digestion, absorption, distribution, metabolism and endocrine regulation that determine glycaemic outcomes [19,20]. These models evaluate fasting glucose, postprandial behaviour, lipid regulation, oxidative markers and β-cell morphology under structured extract exposure. Polysaccharides influence insulin sensitivity, microbiota behaviour, inflammatory tone and β-cell resilience under diabetic conditions [21].

In silico tools complement laboratory systems because docking, pharmacophore modelling and molecular dynamics simulation predict ligand-target complementarity, binding stability and pharmacokinetic suitability for diverse metabolites [22–24]. Multi-target behaviour appears across digestive, oxidative and insulin-linked pathways [25]. Phenolic metabolites influence digestive, oxidative and insulin-associated mechanisms across experimental tiers [26].

Extraction variability, assay divergence, cell-handling inconsistencies and induction-model differences continue to limit cross-study comparison [27,28]. Extraction design influences inhibitory, antioxidant and metabolic behaviour across matched assay conditions [29]. Dietary phenolics influence oxidative behaviour, inflammatory tone and metabolic adaptation under diabetic conditions [30,31]. Harmonised methodological structures linking phytochemical profiling with biochemical, cellular and physiological systems remain necessary. This review integrates multi-tier experimental evidence to clarify mechanistic patterns supporting structured evaluation of plant-derived antidiabetic preparations.

2. Global Burden and Plant-Based Rationale

Global diabetes prevalence continues to rise because persistent hyperglycaemia disrupts vascular, renal and neurological pathways essential for metabolic stability [1]. The steepest increases occur in regions with limited healthcare access because long-term management is constrained by treatment cost, availability and inconsistent adherence [3]. These limitations increase the appeal of plant-based strategies because phytochemicals provide structurally diverse metabolites with recognised biochemical relevance and established historical use [2].

Extracts from *G. sylvestre* support this rationale because this species enhances insulin secretion and influences glycaemic behaviour in experimental systems [5]. Plant metabolites act through pathways regulating fasting glucose, postprandial responses and long-term metabolic control because they modulate digestive enzymes, oxidative behaviour, inflammatory mediators and insulin-linked signalling [4]. These mechanisms include PI3K activity, AKT modulation, AMPK activation and GLUT4 mobilisation and each contributes to metabolic stability under diabetic conditions [4]. Phenolic metabolites influence digestive, oxidative and insulin-associated pathways across experimental tiers [26].

Structural diversity enables extracts to influence multiple molecular sites. Phenolic metabolites frequently inhibit α-amylase and α-glucosidase, while alkaloids and terpenoids modulate insulin-linked signalling and inflammatory pathways through receptor-level interactions [14]. Polysaccharides influence insulin sensitivity, microbiota behaviour, inflammatory tone and β-cell resilience under diabetic conditions [21]. These relationships support evaluation of multiple phytochemical classes across biochemical and physiological tiers.

Extract variability remains common because plant provenance, solvent identity and extraction design alter phytochemical profiles and shape biological outcomes [15,28]. Extraction design influences inhibitory, antioxidant and metabolic behaviour across matched assay conditions [29]. Dietary phenolics influence oxidative behaviour, inflammatory tone and metabolic adaptation under diabetic conditions [30,31].

Earlier studies vary widely in calibration and reporting of digestive enzyme inhibition, glucose handling behaviour, antioxidant activity and *in vivo* glycaemic outcomes because assay parameters differ in substrate identity, enzyme provenance and detection logic [15,28]. Additional variability appears in assays targeting dipeptidyl peptidase 4, protein tyrosine phosphatase 1B and glycation mechanisms because these depend on assay-specific pH, incubation duration and chromogenic systems [16]. Multi-target behaviour appears across digestive, oxidative and insulin-linked pathways [25].

Coordinated methodological tiers address these limitations because they link chemical profiles with functional responses across biochemical, cellular and physiological levels [32]. These frameworks incorporate metabolite profiles, signalling markers and tissue-level outcomes and support more reliable assessment of plant-derived

antidiabetic agents [32]. Metabolomic mapping links phytochemical fingerprints with metabolic and signalling responses across experimental tiers [33]. Structured alignment across these tiers improves interpretive coherence and reduces uncertainty created by heterogeneous extraction, assay divergence and incomplete reporting [27].

3. Methodological Foundations

Biochemical assays form the initial methodological tier because they clarify how plant extracts influence digestive enzymes, oxidative pathways and inflammatory mediators relevant to glycaemic regulation [14,15]. These controlled *in vitro* systems quantify α-amylase and α-glucosidase inhibition using defined substrates, enzyme sources and calibrated detection logic [16,17]. Variability arises when extraction procedures, solvent polarity or constituent stability alter inhibitory magnitude across matched assay conditions [14,15]. Additional *in vitro* assays assess antioxidant behaviour, glycation suppression and dipeptidyl peptidase 4 inhibition and provide early mechanistic signals linked with digestive and redox pathways [16,17]. Phenolic metabolites influence digestive, oxidative and insulin-associated pathways across several methodological tiers [26]. Figure 1 illustrates the integrated biochemical, cellular, *in vivo* and *in silico* tiers that support mechanistic evaluation of plant-derived antidiabetic activity.



Figure 1. Integrated methodological-mechanistic framework for evaluating plant-derived antidiabetic activity.

Cell-based platforms extend biochemical findings because they evaluate glucose uptake, mitochondrial behaviour, oxidative status and GLUT4 mobilisation under physiologically relevant conditions [18]. These assays reveal signalling responses influenced by extract composition, solvent identity and phytochemical distribution, with modulation of AMPK-, PI3K- and AKT-linked pathways in species such as *R. stricta* [6]. Variability appears when serum concentration, differentiation stage, glucose levels or viability controls differ and emphasises the importance of strict methodological consistency [27]. Multi-target behaviour appears across digestive, oxidative and insulin-linked pathways [25]. Figure 2 shows the links between bioactive compound classes and physiological mechanisms relevant to metabolic regulation.



Figure 2. Phytochemical classes mapped to mechanistic pathways relevant to antidiabetic activity.

In vivo models provide physiological integration because they determine whether biochemical and cellular signals persist under metabolic complexity that includes digestion, absorption, distribution, metabolism and endocrine feedback [19,20]. Streptozotocin- and alloxan-based diabetic systems measure fasting glucose, postprandial behaviour, lipid profiles, oxidative markers and β-cell morphology after structured exposure to plant extracts [19,20,34].

Extracts from *P. granatum* show consistent digestive enzyme inhibition, antioxidant behaviour and β-cell preservation across biochemical, cellular and physiological tiers [8]. Polysaccharides influence insulin sensitivity, inflammatory tone and β-cell resilience under *in vivo* diabetic conditions [21]. *In vivo* variability remains substantial because induction dose, fasting duration, strain, age and housing conditions strongly influence metabolic severity [19,35].

In silico approaches complement laboratory systems because docking, pharmacophore modelling and molecular dynamics simulations predict ligand-target complementarity, binding stability and pharmacokinetic suitability for diverse metabolites [22–24]. These computational predictions gain interpretive strength when aligned with enzyme inhibition profiles, glucose-uptake patterns or *in vivo* metabolic outcomes [24]. Multi-target behaviour appears across computational, biochemical and physiological tiers [25].

Multi-tier methodological frameworks therefore integrate biochemical inhibition, cellular signalling behaviour, *in vivo* metabolic responses and *in silico* predictions to support coherent evaluation of plant-derived antidiabetic agents [4,32]. Metabolomic mapping links phytochemical fingerprints with metabolic and signalling responses across experimental tiers [33]. These integrated frameworks reduce uncertainty created by heterogeneous extraction, assay divergence and incomplete reporting [27].

4. Mechanistic Domains

Mechanistic domains describe the biochemical and physiological pathways regulating glucose homeostasis and clarify how plant metabolites influence digestive, oxidative, inflammatory and insulin-linked systems relevant to antidiabetic behaviour [3,4]. These domains form a structural basis for interpretation because phytochemicals converge on shared metabolic nodes or act through distinct regulatory mechanisms shaped by solvent identity and constituent profile [3,4]. Multi-target behaviour appears across digestive, oxidative and insulin-linked pathways [25]. Polysaccharides influence insulin sensitivity, inflammatory tone and β-cell resilience under diabetic conditions [21].

4.1. Digestive Enzyme Regulation

Digestive enzyme regulation forms a core mechanistic domain because α-amylase and α-glucosidase mediate carbohydrate breakdown and postprandial glucose release [15]. Phenolics, terpenoids and alkaloids frequently inhibit these enzymes under controlled *in vitro* conditions and limit glucose liberation [15]. Extracts from *G. officinalis* show strong α-glucosidase inhibition consistent with early biochemical interpretation [12]. Phenolic metabolites influence digestive enzyme behaviour across experimental tiers [26].

Inhibitory magnitude varies because extraction conditions, solvent polarity and phytochemical distribution influence enzyme binding [14]. Kinetic studies identify competitive or non-competitive profiles and clarify metabolite-enzyme interactions that support mechanistic assignment [9]. Extraction design influences inhibitory outcomes across matched assay conditions [29].

4.2. Oxidative Stress Modulation

Oxidative stress modulation forms a second mechanistic domain because persistent hyperglycaemia elevates reactive oxygen species that impair insulin signalling, alter mitochondrial behaviour and destabilise β-cell function [34]. Polyphenols, flavonoids and diterpenes enhance antioxidant capacity through radical-scavenging, metal-chelating and endogenous enzyme-supporting behaviour [34]. These redox effects influence signalling cascades linked with insulin sensitivity and metabolic adaptation and correspond with transcriptional responses identified in multi-omics datasets [7]. Dietary phenolics influence oxidative behaviour, inflammatory tone and metabolic resilience under diabetic conditions [30,31]. Metabolomic mapping links phenolic fingerprints with redox-associated metabolic responses across *in vitro* and *in vivo* tiers [33].

4.3. Inflammatory Pathway Regulation

Inflammatory regulation forms another mechanistic domain because chronic inflammation contributes to insulin resistance and β-cell decline. Extracts from *A. iva* modulate cytokine patterns and suppress NF-κB activity, supporting systemic metabolic stability [11]. Alkaloids, phenolics and terpenoids contribute anti-inflammatory

behaviour, and cellular studies show reduced inflammatory signalling aligned with improved metabolic responses [10,18]. Polysaccharides influence inflammatory mediators and immune-associated pathways linked with metabolic stability [21]. Multi-target behaviour appears across inflammatory and metabolic pathways [25].

4.4. Insulin-Linked Signalling Pathways

Insulin-linked signalling represents a central mechanistic domain because PI3K, AKT, GLUT4 and AMPK regulate glucose uptake and metabolic homeostasis [4]. Flavonoids, diterpenes and polysaccharides enhance GLUT4 mobilisation, activate AMPK and modulate PI3K-associated phosphorylation in *in vitro* systems [4]. These effects support mechanistic coherence across biochemical and cellular tiers. Multi-target behaviour appears across insulin-linked pathways in *in vitro*, *in vivo* and clinical systems [25]. Polysaccharides influence insulin sensitivity and metabolic signalling under diabetic conditions [21].

4.5. β-Cell Function and Pancreatic Resilience

β-Cell resilience forms another mechanistic domain because mitochondrial stability, redox status and membrane excitability determine insulin release under diabetic stress. Extracts with antioxidant or anti-inflammatory properties preserve β-cell morphology and strengthen insulin output in streptozotocin- or alloxan-induced *in vivo* models [19,35,36]. These findings align phytochemical behaviour with endocrine protection and demonstrate continuity from biochemical responses to physiological resilience. Phenolic metabolites influence oxidative behaviour, mitochondrial stability and insulin-associated pathways linked with β-cell preservation [26]. Polysaccharides influence β-cell morphology, inflammatory tone and metabolic resilience under diabetic conditions [21].

5. Phytochemical Composition and Mechanisms

Phytochemical composition determines biochemical and physiological behaviour because structural classes influence digestive enzyme regulation, oxidative modulation, inflammatory control and insulin-linked pathways central to antidiabetic activity [4]. Polyphenols, flavonoids, alkaloids, terpenoids, saponins and polysaccharides contribute distinct mechanistic properties because their scaffolds support hydrogen bonding, π-stacking and redox interactions relevant to metabolic pathways [17,37]. Extraction design alters constituent stability and influences biochemical outcomes [29].

5.1. Structural Classes

Structural diversity allows phytochemicals to influence several biochemical sites. Flavonoids and phenolic acids interact with α-amylase and α-glucosidase because aromatic rings and hydroxyl groups support catalytic-site binding [23,34]. Phenolic metabolites influence digestive, oxidative and insulin-linked pathways across experimental tiers [26]. Alkaloids with nitrogen-bearing scaffolds influence inflammatory and insulin-associated signalling [6]. Terpenoids regulate metabolic behaviour through hydrophobic interactions that modulate AMPK- and PI3K-linked pathways [34]. Polysaccharides influence insulin sensitivity, inflammatory tone and β-cell resilience under diabetic conditions [21]. Multi-target behaviour appears across digestive, oxidative and insulin-linked pathways [25].

5.2. Extract Variability

Extract variability reflects differences in plant provenance, environmental conditions and processing design because these factors define phytochemical distribution [38]. Solvent polarity strongly influences biochemical outcomes because polar extraction enriches phenolic and flavonoid fractions that dominate inhibitory and antioxidant behaviour [17]. Fractionation, drying temperature and membrane techniques alter phenolic stability and produce divergent enzyme-inhibition and redox outcomes across reports [17]. Extraction design influences inhibitory, antioxidant and metabolic behaviour across matched assay conditions [29]. Dietary phenolics influence oxidative behaviour, inflammatory tone and metabolic adaptation under diabetic conditions [30,31].

5.3. Composition-Mechanism Alignment

Mechanistic relevance increases when phytochemical composition aligns with functional assays. Phenolic-rich extracts consistently inhibit α-glucosidase and show strong antioxidant behaviour and support digestive and redox relevance [37]. Phenolic metabolites influence digestive, oxidative and insulin-associated pathways across *in vitro* and *in vivo* tiers [26]. Saponins influence lipid-handling and insulin-linked responses because their

amphiphilic structures interact with membrane-associated signalling domains. Polysaccharides influence insulin sensitivity, inflammatory tone and β-cell resilience under diabetic conditions [21]. Multi-target behaviour appears across digestive, oxidative and insulin-linked pathways [25].

5.4. Multi-Omics Interpretation

Multi-omics datasets clarify functional behaviour because they link phytochemical fingerprints with transcriptional, metabolic and proteomic responses. Transcriptomic, proteomic and metabolomic datasets collectively define the multi-omics domain represented in Figure 3, and these layers provide complementary evidence for signalling and metabolic regulation. Phenolic patterns correspond with redox-linked transcriptional changes and insulin-associated signalling modules identified in cellular and metabolic analyses [7]. Metabolomic mapping links phenolic fingerprints with metabolic and signalling responses across *in vitro* and *in vivo* tiers [33]. Additional multi-omics evidence shows metabolomic shifts that align with phenolic-driven antioxidant pathways and signalling regulation across experimental systems [32,34]. Figure 3 highlights the metabolomic mapping of phytochemical fingerprints to signalling and metabolic outputs within multi-omics frameworks.



Figure 3. Metabolomic mapping of phytochemical fingerprints to signalling and metabolic outputs.

5.5. *Mechanistic Integration across Tiers*

Phytochemical classes integrate across biochemical, cellular and physiological tiers because structural motifs influence digestive enzyme inhibition, antioxidant behaviour, inflammatory regulation and insulin-linked signalling [4]. Polyphenols combine digestive enzyme inhibition with antioxidant and insulin-linked responses that align with multi-omics supported signalling pathways [34]. Terpenoids and alkaloids regulate inflammatory and metabolic systems, while polysaccharides influence glucose-uptake behaviour, oxidative balance and immune-associated responses [20,35]. Multi-target behaviour appears across digestive, oxidative and insulin-linked pathways [25]. Polysaccharides influence insulin sensitivity, inflammatory tone and β-cell resilience under diabetic conditions [21]. Persistent extract heterogeneity continues to limit cross-study interpretation and emphasises the need for harmonised frameworks [28].

6. Phytochemical Classes

Phytochemical classes form a structural basis for interpreting antidiabetic behaviour because plant metabolites display characteristic scaffolds that influence digestive, oxidative, inflammatory and insulin-linked pathways [3,4]. Their chemical diversity explains why extracts act across multiple mechanistic tiers and why variability appears across solvents, assays and biological models [3,4].

6.1. Polyphenols

Polyphenols constitute a major phytochemical group because aromatic rings and hydroxyl groups support digestive enzyme inhibition, antioxidant behaviour and insulin-linked modulation [15]. These compounds inhibit α-amylase and α-glucosidase through defined hydrogen bonding with catalytic residues that limit carbohydrate

breakdown [15]. Polyphenols influence PI3K- and AMPK-linked signalling and improve redox stability and metabolic responsiveness in *in vitro* systems [7,34]. Phenolic metabolites influence digestive, oxidative and insulin-associated pathways across experimental tiers [26]. Multi-omics datasets show phenolic-associated transcriptional patterns linked with antioxidant pathways and insulin-related signalling shifts [7].

6.2. Terpenoids

Terpenoids include monoterpenes, diterpenes and triterpenoids with mechanistic relevance for inflammatory modulation, insulin-linked regulation and β-cell protection [4]. Diterpenes enhance AMPK activation and support GLUT4-mediated glucose uptake, while triterpenoids combine antioxidant and anti-inflammatory actions that stabilise metabolic pathways [20]. Hydrophobic scaffolds influence membrane-associated processes and receptor-linked behaviour and contribute to metabolic improvement across experimental tiers [4]. Multi-target behaviour appears across digestive, oxidative and insulin-linked pathways [25].

6.3. Alkaloids

Alkaloids contribute antidiabetic behaviour through nitrogen-bearing scaffolds that interact with digestive enzymes, inflammatory mediators and insulin-linked targets [6]. Many alkaloids inhibit α-glucosidase with potency influenced by extraction method and constituent integrity [6]. Extracts enriched in alkaloids improve glycaemia and preserve β-cell morphology in streptozotocin- and alloxan-induced *in vivo* systems because they reduce inflammatory tone and support redox balance [19,35]. Alkaloids influence metabolic and inflammatory pathways across biochemical and cellular tiers [25].

6.4. Polysaccharides

Polysaccharides regulate glucose uptake, insulin sensitivity and redox behaviour through high-molecular-weight structures that influence membrane interactions and metabolic signalling [20]. These compounds stabilise glucose handling in hepatic and muscle tissues and support antioxidant defence in *in vivo* systems [20,35]. Polysaccharides influence immune-linked pathways that indirectly support metabolic regulation [35]. They also influence insulin sensitivity, inflammatory tone and β-cell resilience under diabetic conditions [21].

6.5. Extract Variability

Extract variability arises because plant provenance, solvent identity, processing temperature and fractionation logic shape phytochemical distribution [38]. Solvent polarity influences enzymatic and redox outcomes because polar solvents enrich phenolics, whereas less-polar solvents capture terpenoids and alkaloids [17]. Divergent glucose-uptake and redox responses across cell-based models reflect differences in extract composition, assay conditions and viability controls [27]. Extraction design influences inhibitory, antioxidant and metabolic behaviour across matched assay conditions [29]. Dietary phenolics influence oxidative behaviour, inflammatory tone and metabolic adaptation under diabetic conditions [30,31].

6.6. Mechanistic Integration across Tiers

Phytochemical classes integrate across biochemical, cellular and physiological tiers because structural motifs influence digestive enzyme inhibition, antioxidant behaviour, inflammatory regulation and insulin-linked signalling [4]. Polyphenols combine digestive enzyme inhibition with antioxidant and insulin-linked responses consistent with multi-omics supported signalling pathways [34]. Terpenoids and alkaloids regulate inflammatory and metabolic systems, while polysaccharides influence glucose-uptake behaviour, oxidative balance and immune-associated responses [20,35]. Multi-target behaviour appears across digestive, oxidative and insulin-linked pathways [25]. Polysaccharides influence insulin sensitivity, inflammatory tone and β-cell resilience under diabetic conditions [21]. Methodological differences and extract heterogeneity continue to challenge interpretive consistency and strengthen the need for harmonised frameworks [28].

7. Methodological-Mechanistic Integration

Integrated methodological-mechanistic interpretation strengthens evaluation of plant-derived antidiabetic agents because biochemical, cellular, *in silico* and *in vivo* systems reveal complementary aspects of extract behaviour across metabolic pathways [4]. These methodological tiers clarify how phytochemical classes influence digestive enzyme inhibition, oxidative balance, inflammatory regulation and insulin-linked signalling within controlled and physiological settings [3,32].

Biochemical assays form the earliest methodological tier because they define primary mechanistic signals through α-amylase and α-glucosidase inhibition, antioxidant behaviour and glycation suppression under consistent *in vitro* conditions [14,15,17]. These assays reveal dose-dependent inhibitory patterns shaped by extraction design, solvent identity and phytochemical composition [16,17]. Biochemical findings alone cannot predict responses under metabolic complexity and therefore require additional methodological tiers.

Cell-based platforms extend biochemical clarity because they evaluate glucose uptake, mitochondrial behaviour, oxidative status and GLUT4 mobilisation in hepatic, muscle and adipocyte models [18]. These systems identify extract-specific modulation of AMPK-, PI3K- and AKT-linked pathways, including effects observed in *R. stricta* [6]. Variability appears when serum concentration, differentiation stage, glucose levels or viability controls differ and emphasises the importance of strict methodological alignment [27]. Cellular systems therefore validate biochemical hypotheses and demonstrate functional relevance.

In vivo models provide physiological integration because they incorporate digestion, absorption, distribution, metabolism and endocrine feedback that determine glycaemic outcomes [19,20]. Streptozotocin- and alloxan-based diabetic systems assess fasting glucose, postprandial responses, lipid regulation, oxidative markers and β-cell morphology after structured extract exposure [19,20,34]. Extracts from *P. granatum* show consistent inhibitory, antioxidant and β-cell protective behaviour across biochemical, cellular and *in vivo* tiers [8]. Metabolic outcomes vary when induction dose, fasting duration, strain or housing conditions differ [19,35].

In silico approaches complement laboratory systems because docking, pharmacophore modelling and molecular dynamics simulation predict ligand-target complementarity, binding stability and pharmacokinetic suitability for diverse metabolites [22–24]. These computational predictions gain interpretive strength when aligned with enzyme-inhibition profiles, glucose-uptake behaviour or *in vivo* metabolic outcomes [24].

Phytochemical classes integrate across biochemical, cellular and physiological systems because structural motifs influence digestive enzyme inhibition, antioxidant behaviour, inflammatory modulation and insulin-linked signalling [4]. Polyphenols contribute to digestive enzyme inhibition, redox stability and insulin-linked responses consistent with multi-omics identified transcriptional patterns [34]. Terpenoids and alkaloids modulate inflammatory and metabolic pathways, while polysaccharides influence glucose-uptake behaviour, oxidative balance and immune-associated responses across methodological tiers [20,34].

Polysaccharides also influence insulin sensitivity, inflammatory tone and β-cell resilience under diabetic conditions [21]. Multi-target behaviour appears across digestive, oxidative and insulin-linked pathways [25]. Integrated methodological-mechanistic evaluation therefore maps extract chemistry to mechanistic domains across biochemical, cellular, *in silico* and *in vivo* tiers and supports structured assessment of plant-derived antidiabetic preparations [4,32].

8. Methodological Limitations

Methodological limitations arise from extraction variability, assay divergence, incomplete mechanistic mapping and inconsistent reporting because each influences the reliability of plant-derived antidiabetic evidence [4,14]. Extraction variability remains substantial because solvent identity, extraction duration, plant-part selection and handling conditions alter phytochemical composition and generate divergent inhibitory, antioxidant and glucose handling outcomes across studies evaluating similar species [8,34]. These differences generate divergent inhibitory outcomes and metabolic responses, making cross-study interpretation difficult [15,28]. Extraction design influences inhibitory, antioxidant and metabolic behaviour across matched assay conditions [29].

Assay heterogeneity contributes further limitations because digestive enzyme assays differ in substrate identity, enzyme provenance, buffer composition, incubation period and detection method and produce substantial variation in inhibitory strength [9,16]. Divergence appears in antioxidant, glycation and dipeptidyl peptidase 4 inhibition assays because calibration, chromogenic systems and incubation parameters differ across laboratories [15,28]. Cell-based assays introduce additional variability because glucose concentration, serum content, differentiation stage and viability controls differ between studies and influence metabolic and signalling responses [18,27]. Dietary phenolics influence oxidative behaviour, inflammatory tone and metabolic adaptation under diabetic conditions [30,31].

Computational methodologies show similar constraints because docking, pharmacophore modelling and ADMET prediction rely on scoring functions and simulation parameters that differ across platforms [24]. These *in silico* predictions require biochemical and *in vivo* validation because static docking structures do not reflect dynamic protein conformations or solvent effects influencing ligand binding [22,23]. Multi-omics tools remain underused in many extract categories and leave gaps in pathway-level interpretation and mechanistic clarity [7,39]. Metabolomic mapping links phytochemical fingerprints with metabolic and signalling responses across experimental tiers [33].

In vivo variability further affects interpretation because induction models differ in strain, age, fasting duration, vehicle, route and dose and produce diabetic phenotypes of unequal severity [19,35]. Variability in dosing schedule, extract standardisation and treatment length complicates evaluation of glycaemic, lipid and tissue-level outcomes [20,34]. Limited toxicological assessment restricts long-term safety interpretation because few studies evaluate organ-level effects, chronic exposure or metabolic resilience [21].

Phytochemical complexity poses additional challenges because crude extracts contain multiple interacting metabolites with overlapping or opposing biochemical actions [3,4]. Limited fractionation, inconsistent standardisation or incomplete compositional profiling weaken structure-activity interpretation. Inadequate integration of phytochemical fingerprints with biochemical, cellular and physiological outcomes restricts clear mechanistic assignment across experimental tiers [32]. Polysaccharides influence insulin sensitivity, inflammatory tone and β-cell resilience under diabetic conditions [21].

Publication bias and selective reporting reduce interpretive strength because positive findings dominate while neutral or negative outcomes remain under-reported [28,40]. Limited replication, incomplete extraction metadata, inconsistent assay calibration and insufficient methodological transparency weaken confidence across biochemical, cellular, *in silico* and *in vivo* tiers [41]. Multi-target behaviour appears across digestive, oxidative and insulin-linked pathways [25].

9. Future Directions

Future research requires coordinated methodological structures, improved extract standardisation and deeper mechanistic resolution because these strengthen the reliability of plant-derived antidiabetic evidence [4,14]. These needs arise because extraction variability, assay divergence, mechanistic gaps and incomplete reporting restrict comparability and interpretive strength across biochemical, cellular and *in vivo* systems [15,28].

Standardised extraction frameworks represent an essential direction because solvent identity, extraction ratio, processing temperature and plant-part selection strongly influence phytochemical composition and shape biological behaviour [34]. Defined extraction parameters and batch consistency improve reproducibility because they reduce variation in phenolic, flavonoid, alkaloid or terpenoid profiles that regulate digestive enzyme inhibition, antioxidant responses and insulin-linked signalling [8,37]. Extraction design influences inhibitory, antioxidant and metabolic behaviour across matched assay conditions [29].

Harmonised assay methodologies remain essential because digestive enzyme assays require consistent substrate identity, enzyme provenance, incubation conditions and calibration logic to reduce variability in α-amylase and α-glucosidase inhibitory data [14]. Cell-based systems require defined glucose levels, serum content, exposure periods and viability controls to ensure reliable measurement of metabolic and signalling responses [18]. *In vivo* systems require transparent reporting of induction dose, fasting duration, strain, age and housing conditions because these variables determine metabolic severity and extract responsiveness [19,35].

Mechanistic resolution must expand through multi-omics and computational systems because metabolomics, transcriptomics and proteomics identify redox-linked, inflammatory or insulin-associated signatures that correspond with phytochemical patterns [4,7,34]. Metabolomic mapping links phytochemical fingerprints with metabolic and signalling responses across *in vitro* and *in vivo* tiers [33]. *In silico* docking, pharmacophore modelling and molecular dynamics simulation refine target prediction because these methods identify ligand complementarity, energetic stability and predicted pharmacokinetic suitability for complex chemical classes [22,24].

Safety and translational relevance require expanded toxicological evaluation because few studies examine chronic dosing, organ-level responses or metabolic resilience beyond glycaemic markers [20,34,42]. Integrated toxicology frameworks can evaluate extract effects on hepatic, renal and pancreatic structure under prolonged exposure and improve interpretation of long-term suitability.

Publication bias remains an important constraint because positive findings dominate while neutral or negative outcomes remain under-reported [28,40]. Limited replication, incomplete extraction metadata, inconsistent assay calibration and insufficient methodological transparency weaken interpretive confidence across biochemical, cellular, *in silico* and *in vivo* tiers [41]. Dietary phenolics influence oxidative behaviour, inflammatory tone and metabolic adaptation under diabetic conditions [30,31]. Integrated methodological progression remains essential because coordinated biochemical, cellular, computational and *in vivo* systems strengthen mechanistic coherence and support structured assessment of plant-derived antidiabetic preparations [4,32].

10. Conclusions

This review outlines methodological and mechanistic advances that strengthen evaluation of plant-derived antidiabetic agents. Integrated workflows that combine *in vitro*, *in vivo* and *in silico* systems improve interpretive

coherence because they link biochemical signals with cellular behaviour and whole-organism metabolic outcomes. Multi-tier progression reduces uncertainty created by extraction variability, assay divergence and inconsistent reporting across research groups. Extract variability remains a major constraint because differences in plant-part selection, solvent identity and extraction design produce chemically distinct preparations. *In vitro* assays also vary in substrate identity, enzyme source and calibration logic, generating wide differences in inhibitory strength. Computational tools provide mechanistic predictions through docking, modelling and ADMET filtering, but require transparent reporting and consistent methodological settings. *In vivo* models introduce further variation because induction protocol, strain, age and environmental conditions influence metabolic severity and glycaemic behaviour. Despite these limitations, coordinated biochemical, cellular, computational and *in vivo* platforms support more coherent interpretation of extract behaviour across mechanistic tiers. Continued progress requires harmonised extraction frameworks, calibrated assay conditions and improved mechanistic resolution to support reliable assessment and translational development of plant-based antidiabetic interventions.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

Given the role as Editorial Board Member, Lutfun Nahar had no involvement in the peer review of this paper and had no access to information regarding its peer-review process. Full responsibility for the editorial process of this paper was delegated to another editor of the journal. The author declares no conflict of interest.

Use of AI and AI-Assisted Technologies

No AI tools were used in the preparation of this paper.

References

1. Shaw, J.E.; Sicree, R.A.; Zimmet, P.Z. Global estimates of diabetes prevalence for 2010 and 2030. *Diabetes Res. Clin. Pract.* **2010**, *87*, 4–14. https://doi.org/10.1016/j.diabres.2009.10.007.
2. Rahman, M.M.; Dhar, P.S.; Sumaia, S.; et al. Plant-derived bioactive substances as antidiabetic agents: An extensive review. *Biomed. Pharmacother.* **2022**, *152*, 113217. https://doi.org/10.1016/j.biopha.2022.113217.
3. Alam, S.; Sarker, M.M.R.; Sultana, T.N.; et al. Antidiabetic phytochemicals from medicinal plants: Prospective candidates for new drug discovery and development. *Front. Endocrinol.* **2022**, *13*, 800714. https://doi.org/10.3389/fendo.2022.800714.
4. Situmorang, P.C.; Zuhra, C.F.; Lutfia, A.; et al. Harnessing phytochemicals to combat diabetes: Insights into molecular pathways and therapeutic advances. *J. Funct. Foods* **2025**, *128*, 106799. https://doi.org/10.1016/j.jff.2025.106799.
5. Al-Romaiyan, A.; Liu, B.; Asare Anane, H.; et al. A novel *Gymnema sylvestre* extract stimulates insulin secretion from human islets *in vivo* and *in vitro*. *Phytother. Res.* **2010**, *24*, 1370–1376. https://doi.org/10.1002/ptr.3125.
6. Mahmood, R.; Kayani, W.K.; Ahmed, T.; et al. Antidiabetic potential and phytochemical profiling of *Rhazya stricta* root extracts. *BMC Complement. Med. Ther.* **2020**, *20*, 293. https://doi.org/10.1186/s12906-020-03035-x.
7. Yang, J.; Seo, H.-J.; Wang, Y.; et al. Antioxidant potential and *in vitro* antidiabetic activity of *Paeonia japonica* extract and isolated compounds. *Agronomy* **2024**, *14*, 2705. https://doi.org/10.3390/agronomy14112705.
8. Laaraj, N.; Bouhrim, M.; Kharchoufa, L.; et al. Phytochemical analysis, α-glucosidase and α-amylase inhibitory activities and acute toxicity studies of extracts from pomegranate (*Punica granatum*) bark, a valuable agro-industrial by-product. *Foods* **2022**, *11*, 1353. https://doi.org/10.3390/foods11091353.
9. Benayad, O.; Bouhrim, M.; Tiji, S.; et al. Phytochemical profile, α-glucosidase and α-amylase inhibition potential and toxicity evaluation of extracts from *Citrus aurantium* (L.) peel, a valuable by-product from Northeastern Morocco. *Biomolecules* **2021**, *11*, 1555. https://doi.org/10.3390/biom11111555.

10. Abomughaid, M.M.; El Shibani, F.A.A.; Abdulkarim, A.K.; et al. Phytochemical profiling, *in vitro* and *in vivo* antidiabetic activity, and *in silico* studies on *Ajuga iva* (L.) Schreb. *Open Chem.* **2024**, *22*, 20230191. https://doi.org/10.1515/chem-2023-0191.
11. Saidi, S.; Remok, F.; Handaq, N.; et al. Phytochemical profile, antioxidant, antimicrobial and antidiabetic activities of *Ajuga iva* (L.). *Life* **2023**, *13*, 1165. https://doi.org/10.3390/life13051165.
12. Sukhtezari, S.; Sahari, M.A.; Barzegar, M.; et al. *In vitro* antidiabetic and antioxidant activities of *Galega officinalis* extracts. *Food Sci. Nutr.* **2024**, *12*, 8137–8149. https://doi.org/10.1002/fsn3.4326.
13. Zehra, S.A.; Bhattarai, P.; Zhang, J.; et al. *In vitro* and *in vivo* evaluation of the antidiabetic activity of *Solidago virgaurea* extracts. *Curr. Bioact. Compd.* **2022**, *19*, e150622206034. https://doi.org/10.2174/1573407218666220615143502.
14. Ardalani, H.; Hejazi Amiri, F.; Hadipanah, A.; et al. Potential antidiabetic phytochemicals in plant roots: A review of *in vivo* studies. *J. Diabetes Metab. Disord.* **2021**, *20*, 1837–1854. https://doi.org/10.1007/s40200-021-00853-9.
15. Bashkin, A.; Ghanim, M.; Abu Farich, B.; et al. Forty-one plant extracts screened for dual antidiabetic and antioxidant functions: Evaluating the types of correlation between α-amylase inhibition and free radical scavenging. *Molecules* **2021**, *26*, 317. https://doi.org/10.3390/molecules26020317.
16. Kidane, Y.; Bokrezion, T.; Mebrahtu, J.; et al. *In vitro* inhibition of α-amylase and α-glucosidase by extracts from *Psiadia punctulata* and *Meriandra bengalensis*. *Evid. Based Complement. Alternat. Med.* **2018**, *2018*, 2164345. https://doi.org/10.1155/2018/2164345.
17. Mokhtari, M.; Chabani, S.; Mouffouk, S.; et al. Phytochemicals, antihemolytic, anti-inflammatory, antioxidant, and antibacterial activities from *Thymus algeriensis*. *J. Liq. Chromatogr. Relat. Technol.* **2021**, *44*, 253–266. https://doi.org/10.1080/10496475.2021.1891174.
18. Paun, G.; Neagu, E.; Albu, C.; et al. *In vitro* antidiabetic and anti-inflammatory activities of polyphenolic-rich extracts from *Anchusa officinalis* and *Melilotus officinalis*. *ACS Omega* **2020**, *5*, 13014–13022. https://doi.org/10.1021/acsomega.0c00929.
19. Wakene, W.; Asmamaw, S.; Kahaliw, W. Evaluation of antidiabetic and antioxidant activity of leaf extract and solvent fractions of *Hypoestes forskaolii* (Val) (Acanthaceae) in mice. *J. Exp. Pharmacol*. **2021**, *13*, 859–872. https://doi.org/10.2147/JEP.S318696.
20. Belayneh, Y.M.; Birhanu, Z.; Birru, E.M.; et al. Evaluation of in vivo antidiabetic, antidyslipidemic, and in vitro antioxidant activities of hydromethanolic root extract of *Datura stramonium* L. (Solanaceae). *J. Exp. Pharmacol.* **2019**, *11*, 29–38. https://doi.org/10.2147/JEP.S192264.
21. He, D.; Cui, C. Plant heteropolysaccharides as potential anti-diabetic agents: A review. *Curr. Issues Mol. Biol.* **2025**, *47*, 533. https://doi.org/10.3390/cimb47070533.
22. Pereira, A.S.P.; Banegas Luna, A.J.; Peña García, J.; et al. Evaluation of the anti-diabetic activity of common herbs and spices: Providing new insights with inverse virtual screening. *Molecules* **2019**, *24*, 4030. https://doi.org/10.3390/molecules24224030.
23. Goulas, V.; Banegas Luna, A.J.; Constantinou, A.; et al. Computational screening of multi-target antidiabetic properties of phytochemicals in Mediterranean plants. *Plants* **2022**, *11*, 1637. https://doi.org/10.3390/plants11131637.
24. Kumar, V.; Sharma, N.; Mishra, V.K.; et al. Computational evaluation of phytocompounds from selective medicinal plants as potential antidiabetic agents. *Chem. Biodivers.* **2025**, *22*, e202403368. https://doi.org/10.1002/cbdv.202403368.
25. Kannan, K.; George, J.A.; Sahadevan, R.; et al. Insights into one drug, multi-target aspects of polyphenols for diabetes management: In *vitro*, *in vivo* and clinical evidence. *Phytochem. Rev.* **2025**, *24*, 4545–4593. https://doi.org/10.1007/s11101-024-10047-9.
26. Shahidi, F.; Danielski, R. Review on the role of polyphenols in preventing and treating type 2 diabetes: Evidence from *in vitro* and *in vivo* studies. *Nutrients*. **2024**, *16*, 3159. https://doi.org/10.3390/nu16183159.
27. Odeyemi, S.; Dewar, J. *In vitro* antidiabetic activity affecting glucose uptake in HepG2 cells exposed to *Lauridia tetragona* extracts. *Processes* **2020**, *8*, 33. https://doi.org/10.3390/pr8010033.
28. Yikna, B.B.; Yehualashet, A.S. Medicinal plant extracts evaluated *in vitro* and *in vivo* for antidiabetic activities in ethiopia: Bases for future clinical trials and related investigations. *Evid.-Based Complement. Alternat. Med.* **2021**, *2021*, 9108499. https://doi.org/10.1155/2021/9108499.
29. Mueed, A.; Shibli, S.; Al-Quwaie, D.A.; et al. Extraction and characterization of polyphenols from certain medicinal plants and evaluation of their antioxidant, antitumor, antidiabetic and antimicrobial properties and potential use in human nutrition. *Front. Nutr.* **2023**, *10*, 1125106. https://doi.org/10.3389/fnut.2023.1125106.
30. Aryal, D.; Joshi, S.; Thapa, N.K.; et al. Dietary phenolic compounds as promising therapeutic agents for diabetes and its complications: A comprehensive review. *Food Sci. Nutr.* **2024**, *20*, 3983. https://doi.org/10.1002/fsn3.3983.
31. Martiniakova, M.; Sarocka, A.; Penzes, N.; et al. Protective role of dietary polyphenols in the management and treatment of type 2 diabetes mellitus. *Nutrients*. **2025**, *17*, 275. https://doi.org/10.3390/nu17020275.

32. Gavanji, S.; Bakhtari, A.; Abdel-Latif, R.; et al. Experimental approaches for induction of diabetes mellitus and assessment of antidiabetic activity: An *in vitro* and *in vivo* methodological review. *Fundam. Clin. Pharmacol.* **2024**, *38*, 842–861. https://doi.org/10.1111/fcp.13009.
33. Ahmad, M.A.; Bhat, S.H.; Iqra, Z.; et al. Unveiling the therapeutic potential: Metabolomics insights into medicinal plants and their antidiabetic effects. *Curr. Food Sci. Tech. Rep.* **2024**, *2*, 91–109. https://doi.org/10.1007/s43555-024-00022-y.
34. Elbermawi, A.; Darwish, M.S.; Zaki, A.A.; et al. In vitro antidiabetic, antioxidant, and prebiotic activities of the chemical compounds isolated from *Guizotia abyssinica*. *Antioxidants.* **2022**, *11*, 2482. https://doi.org/10.3390/antiox11122482.
35. Kifle, Z.D.; Yesuf, J.S.; Atnafie, S.A. Evaluation of in vitro and in vivo anti-diabetic, anti-hyperlipidemic, and antioxidant activity of flower crude extract and solvent fractions *of Hagenia abyssinica* (Rosaceae). *J. Exp. Pharmacol.* **2020**, *12*, 151–167. https://doi.org/10.2147/JEP.S249964.
36. Ansari, P.; Flatt, P.R.; Harriott, P.; et al. Evaluation of the antidiabetic and insulin-releasing effects of Annona squamosa, including isolation and characterization of active phytochemicals. *Plants* **2020**, *9*, 1348. https://doi.org/10.3390/plants9101348.
37. Agawane, S.B.; Gupta, V.S.; Kulkarni, M.J.; et al. Chemo-biological evaluation of antidiabetic activity of *Mentha arvensis* L. and its role in inhibition of advanced glycation end products. *J. Ayurveda Integr. Med.* **2019**, *10*, 166–170. https://doi.org/10.1016/j.jaim.2017.07.003.
38. Neagu, E.; Paun, G.; Albu, C.; et al. In vitro assessment of the antidiabetic and anti-inflammatory potential of *Artemisia absinthium*, *Artemisia vulgaris*, and *Trigonella foenum-graecum* extracts processed using membrane technologies. *Molecules.* **2023**, *28*, 7156. https://doi.org/10.3390/molecules28207156.
39. Rossafi, B.; Bouribab, A.; Abchir, O.; et al. Antidiabetic potential of Moroccan medicinal plant extracts: A virtual screening using *in silico* approaches. *Results Chem.* **2025**, *16*, 102365. https://doi.org/10.1016/j.rechem.2025.102365.
40. Hussain, I.; Janjua, M.R.S.A.; Haq, A.U.; et al. Evaluation of anti-infection and anti-diabetic activities in methanolic and *n*-hexane plant extracts of indigenously cultivated *Chenopodium album*. *Agronomy.* **2024**, *14*, 1340. https://doi.org/10.3390/agronomy14071340.
41. Carvalho, I.S.; Viegas, C.; Markiewicz, M.; et al. Plant-based potential in diabetes management: *In vitro* antioxidant, wound-healing, and enzyme inhibitory activities of southern algarve species. *Molecules* **2025**, *30*, 2432. https://doi.org/10.3390/molecules30112432.
42. Aljazzaf, B.; Regeai, S.; Elghmasi, S.; et al. Evaluation of antidiabetic effect of combined leaf and seed extracts of *Moringa oleifera* (Moringaceae) on alloxan-induced diabetes in mice: A biochemical and histological study. *Oxid. Med. Cell. Longev.* **2023**, *2023*, 9136217. https://doi.org/10.1155/2023/9136217.